Witryna18 wrz 2024 · As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with NSCLC, SCLC, bladder cancer, hepatocellular carcinoma, biliary tract cancer (a form of liver cancer), oesophageal cancer, gastric and gastroesophageal cancer, cervical … Witryna11 lis 2024 · Imfinzi is approved in the US and several other countries in combination with chemotherapy for the treatment of locally advanced or metastatic biliary tract cancer based on the TOPAZ-1 Phase III trial, and it is approved with Imjudo in the US for the treatment of unresectable hepatocellular carcinoma based on the HIMALAYA …
Imfinzi: Pending EC decision European Medicines Agency
WitrynaIMFINZI is a prescription medicine used to treat adults with a type of cancer called biliary tract cancer (BTC), including cancer of the bile ducts (cholangiocarcinoma) … Witryna25 paź 2024 · Imfinzi plus chemotherapy significantly improved overall survival in 1st-line advanced biliary tract cancer in TOPAZ-1 Phase III trial at interim analysis. First immunotherapy combination to demonstrate superior clinical outcomes. over standard of care in a global, randomised trial in this setting. Positive high-level results from the … damaged usb recovery
Durvalumab Improves Survival in Bile Duct Cancers - NCI
Witryna26 paź 2024 · About Biliary Tract Cancer. Biliary tract cancers are a group of rare and aggressive gastrointestinal cancers that form in the cells of the bile ducts (cholangiocarcinoma), gallbladder or ampulla of Vater (where the bile duct and pancreatic duct connect to the small intestine). 1,2 Cholangiocarcinoma is more … Witryna13 sty 2024 · A second late-breaking presentation will highlight results from the TOPAZ-1 Phase III trial for Imfinzi plus chemotherapy in advanced biliary tract cancer, which was unblinded early at an interim analysis in October 2024 due to clear evidence of efficacy. Witryna24 mar 2024 · The CALLA Phase III trial for AstraZeneca’s Imfinzi (durvalumab) given concurrently with chemoradiotherapy (CRT) did not achieve statistical significance for the primary endpoint of improving progression-free survival (PFS) versus CRT alone in the treatment of patients with locally advanced cervical cancer.. Bradley Monk, MD, … damaged usb port laptop